Zhang Y, Riesterer C, Ayrall A M, Sablitzky F, Littlewood T D, Reth M
MPI für Immunbiologie, D-79108 Freiburg, Germany.
Nucleic Acids Res. 1996 Feb 15;24(4):543-8. doi: 10.1093/nar/24.4.543.
The site-directed recombinase Cre can be employed to delete or express genes in cell lines or animals. Clearly, the ability to control remotely the activity of this enzyme would be highly desirable. To this end we have constructed expression vectors for fusion proteins consisting of the Cre recombinase and a mutated hormone-binding domain of the murine oestrogen receptor. The latter still binds the anti-oestrogen drug tamoxifen but no longer 17 beta-oestradiol. We show here that in embryonic stem cells expressing such fusion proteins, tamoxifen can efficiently induce Cre-mediated recombination, thereby activating a stably integrated LacZ reporter gene. In the presence of either 10 microM tamoxifen or 800 nM 4-hydroxy-tamoxifen, recombination of the LacZ gene is complete within 3-4 days. By placing a tamoxifen-binding domain on both ends of the Cre protein, the enzymatic activity of Cre can be even more tightly controlled. Transgenic mice expressing such an tamoxifen-inducible Cre enzyme may thus provide a new and useful genetic tool to mutate or delete genes at specific times during development or in adult animals.
位点特异性重组酶Cre可用于在细胞系或动物中删除或表达基因。显然,能够远程控制这种酶的活性将是非常理想的。为此,我们构建了融合蛋白的表达载体,该融合蛋白由Cre重组酶和小鼠雌激素受体的突变激素结合结构域组成。后者仍能结合抗雌激素药物他莫昔芬,但不再结合17β-雌二醇。我们在此表明,在表达此类融合蛋白的胚胎干细胞中,他莫昔芬可有效诱导Cre介导的重组,从而激活稳定整合的LacZ报告基因。在存在10μM他莫昔芬或800 nM 4-羟基他莫昔芬的情况下,LacZ基因的重组在3-4天内完成。通过在Cre蛋白的两端放置他莫昔芬结合结构域,Cre的酶活性可以得到更严格的控制。表达这种他莫昔芬诱导型Cre酶的转基因小鼠因此可能提供一种新的有用的遗传工具,用于在发育过程中的特定时间或成年动物中使基因发生突变或删除。